Skip to main content

Advertisement

Log in

Significant Role of Palliative Gastrectomy in Selective Gastric Cancer Patients with Peritoneal Dissemination: A Propensity Score Matching Analysis

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Objective

The aim of this study was to explore whether palliative gastrectomy is suitable for gastric cancer patients with peritoneal metastasis, and for patients in whom the type of peritoneal metastasis should be selected to receive palliative gastrectomy.

Methods

A total of 747 patients diagnosed with gastric adenocarcinoma with peritoneal metastasis at our centers between January 2000 and April 2014 were retrospectively analyzed. After propensity score matching, the clinicopathologic characteristics and clinical outcomes of patients with peritoneal dissemination were analyzed.

Results

After propensity score matching, the median overall survival (OS) of patients in the gastrectomy group was longer than that for patients in the non-gastrectomy group (11.87 vs. 9.27 months; p = 0.020). Patients who received first-line chemotherapy had a significantly longer median OS than those who did not (11.97 vs. 7.03 months; p < 0.001); among these patients, those undergoing more than eight periods of first-line chemotherapy benefited the most (p < 0.001). Subgroup analyses revealed that patients classified as P1 who were undergoing chemotherapy benefited from gastrectomy (p = 0.024), and patients without multisite metastasis also benefited from gastrectomy with regard to OS (p = 0.007). In the multivariate survival analysis, multisite distant metastasis was the independent poor prognostic factor (p < 0.001), while palliative gastrectomy (p = 0.006) and a period of first-line chemotherapy (p < 0.001) were good prognostic factors. Morbidity rates in the gastrectomy and non-gastrectomy groups were 10.4 and 1.0 %, respectively (p = 0.003); however, no difference in mortality was noted between the two groups (p = 0.590).

Conclusions

Palliative gastrectomy can prolong the survival of P1 patients without multisite distant metastasis when combined with more than five periods, and particularly more than eight periods, of first-line chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.

    Article  PubMed  Google Scholar 

  2. Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439–49.

    Article  PubMed  Google Scholar 

  3. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21.

    Article  CAS  PubMed  Google Scholar 

  4. Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.

    Article  CAS  PubMed  Google Scholar 

  5. Chen S, Li YF, Feng XY, et al. Significance of palliative gastrectomy for late-stage gastric cancer patients. J Surg Oncol. 2012;106:862–71.

    Article  PubMed  Google Scholar 

  6. Zhang XF, Huang CM, Lu HS, et al. Surgical treatment and prognosis of gastric cancer in 2,613 patients. World J Gastroenterol. 2004;10:3405–08.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Hioki M, Gotohda N, Konishi M, et al. Predictive factors improving survival after gastrectomy in gastric cancer patients with peritoneal carcinomatosis. World J Surg. 2010;34:555–62.

    Article  PubMed  Google Scholar 

  8. Sugarbaker PH, Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology. 2000;58(2):96–107.

    Article  CAS  PubMed  Google Scholar 

  9. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.

    Article  CAS  PubMed  Google Scholar 

  10. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.

    Article  CAS  PubMed  Google Scholar 

  11. Bernards N, Creemers GJ, Nieuwenhuijzen GA, et al. No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Ann Oncol. 2013;24:3056–60.

    Article  CAS  PubMed  Google Scholar 

  12. Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18:1575–81.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Yang K, Liu K, Zhang WH, et al. The value of palliative gastrectomy for gastric cancer patients with intraoperatively proven peritoneal seeding. Medicine (Baltimore) 2015;94:e1051.

    Article  Google Scholar 

  14. Xia X, Li C, Yan M, et al. Who will benefit from noncurative resection in patients with gastric cancer with single peritoneal metastasis? Am Surg. 2014;80:124–30.

    PubMed  Google Scholar 

  15. He MM, Zhang DS, Wang F, et al. The role of non-curative surgery in incurable, asymptomatic advanced gastric cancer. PLoS One. 2013;8:e83921.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Lasithiotakis K, Antoniou SA, Antoniou GA, et al. Gastrectomy for stage IV gastric cancer. a systematic review and meta-analysis. Anticancer Res. 2014;34:2079–85.

    PubMed  Google Scholar 

  17. Sun J, Song Y, Wang Z, et al. Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer. 2013;13:577.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Tokunaga M, Terashima M, Tanizawa Y, et al. Survival benefit of palliative gastrectomy in gastric cancer patients with peritoneal metastasis. World J Surg. 2012;36:2637–43.

    Article  PubMed  Google Scholar 

  19. Kokkola A, Louhimo J, Puolakkainen P. Does non-curative gastrectomy improve survival in patients with metastatic gastric cancer? J Surg Oncol. 2012;106:193–96.

    Article  PubMed  Google Scholar 

  20. Ouchi K, Sugawara T, Ono H, et al. Therapeutic significance of palliative operations for gastric cancer for survival and quality of life. J Surg Oncol. 1998;69:41–44.

    Article  CAS  PubMed  Google Scholar 

  21. Japanese Research Society for Gastric Cancer (1995) Japanese classification of gastric carcinoma, 1st English edn. Kanehara & Co., Ltd, Tokyo.

    Google Scholar 

  22. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150:327–33.

    Article  CAS  PubMed  Google Scholar 

  23. Garrido MM, Kelley AS, Paris J, et al. Methods for constructing and assessing propensity scores. Health Serv Res. 2014;49:1701–20.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Bando E, Yonemura Y, Takeshita Y, et al. Intraoperative lavage for cytological examination in 1297 patients with gastric carcinoma. Am J Surg. 1999;178:256–62.

    Article  CAS  PubMed  Google Scholar 

  25. Fujitani K, Yang HK, Kurokawa Y, et al. Randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor: Japan Clinical Oncology Group Study JCOG 0705 and Korea Gastric Cancer Association Study KGCA01. Jpn J Clin Oncol. 2008;38:504–506.

    Article  PubMed  Google Scholar 

  26. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14:e218–28.

    Article  CAS  PubMed  Google Scholar 

  27. Dittmar Y, Rauchfuss F, Goetz M, et al. Non-curative gastric resection for patients with stage 4 gastric cancer: a single center experience and current review of literature. Langenbecks Arch Surg. 2012;397:745–53.

    Article  PubMed  Google Scholar 

  28. Chang YR, Han DS, Kong SH, et al. The value of palliative gastrectomy in gastric cancer with distant metastasis. Ann Surg Oncol. 2012;19:1231–39.

    Article  PubMed  Google Scholar 

  29. Hartgrink HH, Putter H, Klein Kranenbarg E, et al. Value of palliative resection in gastric cancer. Br J Surg. 2002;89:1438–43.

    Article  CAS  PubMed  Google Scholar 

  30. Medina-Franco H, Contreras-Saldivar A, Ramos-De La Medina A, et al. Surgery for stage IV gastric cancer. Am J Surg. 2004;187:543–46.

    Article  PubMed  Google Scholar 

  31. Sano T, Sasako M, Yamamoto S, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy. Japan Clinical Oncology Group Study 9501. J Clin Oncol. 2004;22:2767–73.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Dr. Zhiwei Zhou, Yuanfang Li, and Yupei Chen for their encouragement, support and valuable statistical help. This work was supported in part by a grant from the National Natural Science Foundation of China (81,302,144) and the Guangdong Science and Technology Department (No. 2012B0617000879).

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Jun-Sheng Peng MD, PhD or Ying-Bo Chen MD.

Ethics declarations

Disclosures

Run-Cong Nie, Shi Chen, Shu-Qiang Yuan, Xiao-Jiang Chen, Yong-Ming Chen, Bao-Yan Zhu, Hai-bo Qiu, Jun-Sheng Peng, and Ying-Bo Chen report no financial disclosures.

Additional information

Run-Cong Nie, Shi Chen, and Shu-Qiang Yuan have contributed equally to this study.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nie, RC., Chen, S., Yuan, SQ. et al. Significant Role of Palliative Gastrectomy in Selective Gastric Cancer Patients with Peritoneal Dissemination: A Propensity Score Matching Analysis. Ann Surg Oncol 23, 3956–3963 (2016). https://doi.org/10.1245/s10434-016-5223-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-016-5223-2

Keywords

Navigation